1051899-19-4

Basic information

• Product Name: 4-(3-iodo-5-nitrophenyl)-morpholine
• Synonyms: 4-(3-iodo-5-nitrophenyl)-morpholine
• CAS NO: 1051899-19-4
• Molecular Weight: 334.113
• Mol File: 1051899-19-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-(3-iodo-5-nitrophenyl)-morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-iodo-5-nitrophenyl)-morpholine(1051899-19-4)
• EPA Substance Registry System: 4-(3-iodo-5-nitrophenyl)-morpholine(1051899-19-4)

Safety Data

• Hazardous Substances Data: 1051899-19-4(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 3819-88-3 1-fluoro-3-iodo-5-nitrobenzene 

Downstream Products

• 1051899-96-7 4-(3-nitro-5-thiomorpholin-4-yl-phenyl)morpholine 
• 1051899-29-6 8-(3-morpholino-5-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 1051899-25-2 (S)-3-(3-methylmorpholino)-5-morpholinoaniline 
• 1051901-15-5 4,4'-(5,5'-dinitrobiphenyl-3,3'-diyl)dimorpholine 
• 1051899-47-8 tert-butyl 4-(3-morpholino-5-nitrophenyl)piperazine-1-carboxylate 
• 1051901-13-3 C₇H₅IN₂O₃ 
• 1051901-11-1 C₈H₉IN₂O₃ 
• 1051899-21-8 4-(3-iodo-5-nitrophenyl)morpholin-3-one 
• 10394-64-6 3-nitro-5-iodoaniline 
• 1129540-90-4 4-[3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine 
• 1312503-17-5 dicyclopropyl{5-[3-(morpholin-4-yl)-5-{[4-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl]-1,3-thiazol-2-yl}methanol 
• 1312537-01-1 {5-[3-amino-5-(morpholin-4-yl)phenyl]-1,3-thiazol-2-yl}(dicyclopropyl)methanol 
• 1312537-00-0 dicyclopropyl{5-[3-(morpholin-4-yl)-5-nitrophenyl]-1,3-thiazol-2-yl}methanol 
• 1051899-50-3 tert-butyl 4-(3-(4-((5-methoxy-2-methylphenyl)(methyl)amino)pyrimidin-2-ylamino)-5-morpholinophenyl)piperazine-1-carboxylate 

Relevant articles and documents

Development of indazolylpyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers

Due to their essential role in the pathogenesis of cancer, members of the Eph (erythropoietin-producing hepatoma cell line-A2) receptor tyrosine kinase family represent promising candidates for molecular imaging. Thus, the development and preparation of novel radiotracers for the noninvasive imaging of the EphB4 receptor via positron emission tomography (PET) is described. First in silico investigations with the indazolylpyrimidine lead compound which is known to be highly affine to EphB4 were executed to identify favorable labeling positions for an introduction of fluorine-18 to retain the affinity. Based on this, reference compounds as well as precursors were developed and labeled with carbon-11 and fluorine-18, respectively. For this purpose, a protecting group strategy essentially had to be generated to prevent unwanted methylation and to enable the introduction of fluorine-18. Further, a convenient radiolabeling strategy using [11C]methyl iodide was established which afforded the isotopically labeled radiotracer in 30-35% RCY (d.c.) which is identical with the original inhibitor molecule. A spiro ammonium precursor was prepared for radiolabeling with fluorine-18. Unfortunately, the labeling did not lead to the desired 18F-radiotracer under the chosen conditions.

HETEROCYCLIC INHIBITORS OF PCSK9

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.

SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS

The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy,Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.